Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon

P A Calabresi1, L R Tranquill, J M Dambrosia

  • 1Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA.

Annals of Neurology
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: P2X7R-dependent regulation of glycogen synthase kinase 3β and claudin-18 in alveolar epithelial type I cells of mice lung.

Histochemistry and cell biology·2018
Same author

The Gulf War era multiple sclerosis cohort: 3. Early clinical features.

Acta neurologica Scandinavica·2017
Same author

Novel Syntrophic Populations Dominate an Ammonia-Tolerant Methanogenic Microbiome.

mSystems·2016
Same author

P2X7R-dependent regulation of glycogen synthase kinase 3β and claudin-18 in alveolar epithelial type I cells of mice lung.

Histochemistry and cell biology·2016
Same author

Improved metagenome assemblies and taxonomic binning using long-read circular consensus sequence data.

Scientific reports·2016
Same author

A red-shifted photochromic sulfonylurea for the remote control of pancreatic beta cell function.

Chemical communications (Cambridge, England)·2015
Same journal

Diabetes and the Metabolic Syndrome as Drivers of Neurodegeneration: Convergent Mechanisms Linking Peripheral Neuropathy and Dementia.

Annals of neurology·2026
Same journal

Sex Differences in the Association of Simultaneous Decline in Blood Pressure and Decline in Cognition during Aging.

Annals of neurology·2026
Same journal

Neurophysiological Recovery Following Nerve Transfer Surgery to Restore Upper Limb Function after Cervical Spinal Cord Injury.

Annals of neurology·2026
Same journal

A new Patient-Reported Outcome Scale to assess autoimmune Encephalitis: PROSE.

Annals of neurology·2026
Same journal

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same journal

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
See all related articles

Interferon beta-1b treatment for multiple sclerosis increases soluble vascular cell adhesion molecule-1 (sVCAM-1). This increase correlates with fewer MRI-detected active lesions, suggesting a novel mechanism involving the adhesion cascade.

Area of Science:

  • Neuroimmunology
  • Molecular Medicine

Background:

  • Interferon beta-1b is a multiple sclerosis (MS) treatment, but its mechanism remains unclear.
  • MS disease activity is monitored using MRI, including contrast-enhancing lesions.

Purpose of the Study:

  • To investigate the relationship between soluble adhesion molecule levels and reduced MRI-detected lesions in MS patients treated with interferon beta-1b.
  • To explore a potential mechanism of action for interferon beta-1b.

Main Methods:

  • Monthly serum samples were analyzed for soluble adhesion molecules (sVCAM-1, ICAM-1, E-selectin, L-selectin) and TNF receptor (60 kd) in MS patients before and during interferon beta-1b treatment.
  • Levels were correlated with the number of contrast-enhancing lesions on monthly MRI scans.

Main Results:

Related Experiment Videos

  • Soluble vascular cell adhesion molecule-1 (sVCAM-1) levels were significantly elevated during interferon beta-1b treatment compared to pre-treatment and healthy controls.
  • Increased sVCAM-1 levels correlated with a reduction in contrast-enhancing lesions on MRI.
  • Other tested adhesion molecules and TNF receptor levels did not show significant changes.

Conclusions:

  • Interferon beta-1b may exert its therapeutic effect in MS by interfering with the adhesion cascade.
  • This interference could limit the trafficking of activated T cells into the central nervous system, reducing inflammation.